[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Brentuximab vedotin.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Brentuximab vedotin.]
[L04AA27, fingolimod, Brentuximab vedotin may increase the immunosuppressive activities of Fingolimod.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Brentuximab vedotin.]
[M04AB02, sulfinpyrazone, The metabolism of Brentuximab vedotin can be increased when combined with Sulfinpyrazone.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Brentuximab vedotin.]
[L02BA01, tamoxifen, The serum concentration of Brentuximab vedotin can be increased when it is combined with Tamoxifen.]
[L01CB02, teniposide, The metabolism of Brentuximab vedotin can be decreased when combined with Teniposide.]
[B01AE07, dabigatran etexilate, The serum concentration of Brentuximab vedotin can be increased when it is combined with Dabigatran etexilate.]
[G03BA03, testosterone, The metabolism of Brentuximab vedotin can be increased when combined with Testosterone.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Tetracaine.]
[S03AA02, tetracycline, The metabolism of Brentuximab vedotin can be decreased when combined with Tetracycline.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Brentuximab vedotin.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Brentuximab vedotin.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Brentuximab vedotin.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Eribulin.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be decreased when combined with Brentuximab vedotin.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Brentuximab vedotin.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Brentuximab vedotin.]
[N06AX05, trazodone, The serum concentration of Brentuximab vedotin can be decreased when it is combined with Trazodone.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Brentuximab vedotin.]
[S01BA05, triamcinolone, The metabolism of Brentuximab vedotin can be increased when combined with Triamcinolone.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Brentuximab vedotin.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Fluclorolone.]
[R03BA07, mometasone, The metabolism of Brentuximab vedotin can be increased when combined with Mometasone.]
[J01FA08, troleandomycin, The metabolism of Brentuximab vedotin can be decreased when combined with Troleandomycin.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Brentuximab vedotin.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Belimumab.]
[L01FX04, ipilimumab, The risk or severity of adverse effects can be increased when Ipilimumab is combined with Brentuximab vedotin.]
[L01EX04, vandetanib, The serum concentration of Brentuximab vedotin can be increased when it is combined with Vandetanib.]
[A10BH05, linagliptin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Brentuximab vedotin can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The serum concentration of Brentuximab vedotin can be increased when it is combined with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Brentuximab vedotin can be decreased when combined with Rilpivirine.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Belatacept is combined with Brentuximab vedotin.]
[B01AF01, rivaroxaban, The serum concentration of Brentuximab vedotin can be increased when it is combined with Rivaroxaban.]
[R03AC18, indacaterol, The serum concentration of Brentuximab vedotin can be increased when it is combined with Indacaterol.]
[B01AC24, ticagrelor, The serum concentration of Brentuximab vedotin can be increased when it is combined with Ticagrelor.]
[C08DA01, verapamil, The serum concentration of Brentuximab vedotin can be increased when it is combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Brentuximab vedotin can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Brentuximab vedotin can be increased when combined with Vinblastine.]
[L01CA02, vincristine, The metabolism of Vincristine can be decreased when combined with Brentuximab vedotin.]
[L01CA03, vindesine, The metabolism of Vindesine can be decreased when combined with Brentuximab vedotin.]
[A11HA03, vitamin E, The metabolism of Brentuximab vedotin can be increased when combined with Vitamin E.]
[B01AA03, warfarin, The serum concentration of Warfarin can be increased when it is combined with Brentuximab vedotin.]
[J05AF01, zidovudine, The risk or severity of adverse effects can be increased when Zidovudine is combined with Brentuximab vedotin.]
[N05AF05, zuclopenthixol, The metabolism of Brentuximab vedotin can be decreased when combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Brentuximab vedotin can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The serum concentration of Brentuximab vedotin can be increased when it is combined with Vemurafenib.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Antilymphocyte immunoglobulin (horse).]
[S01AA13, fusidic acid, The metabolism of Brentuximab vedotin can be decreased when combined with Fusidic acid.]
[L01ED01, crizotinib, The metabolism of Brentuximab vedotin can be decreased when combined with Crizotinib.]
[R03DC01, zafirlukast, The metabolism of Brentuximab vedotin can be decreased when combined with Zafirlukast.]
[N05AE04, ziprasidone, The metabolism of Brentuximab vedotin can be decreased when combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Brentuximab vedotin can be decreased when combined with Drospirenone.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Brentuximab vedotin.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be decreased when combined with Brentuximab vedotin.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Brentuximab vedotin.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Brentuximab vedotin.]
[J02AC03, voriconazole, The metabolism of Brentuximab vedotin can be decreased when combined with Voriconazole.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Brentuximab vedotin.]
[R07AX02, ivacaftor, The serum concentration of Brentuximab vedotin can be increased when it is combined with Ivacaftor.]
[H02AB11, prednylidene, The metabolism of Brentuximab vedotin can be increased when combined with Prednylidene.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Brentuximab vedotin.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Azacitidine is combined with Brentuximab vedotin.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Azathioprine is combined with Brentuximab vedotin.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Brentuximab vedotin.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Brentuximab vedotin.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Brentuximab vedotin.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Brentuximab vedotin.]
[L01FD02, pertuzumab, The risk or severity of adverse effects can be increased when Pertuzumab is combined with Brentuximab vedotin.]
[G04BD12, mirabegron, The serum concentration of Brentuximab vedotin can be increased when it is combined with Mirabegron.]
[L01XG02, carfilzomib, The serum concentration of Brentuximab vedotin can be increased when it is combined with Carfilzomib.]
[V03AX03, cobicistat, The serum concentration of Brentuximab vedotin can be increased when it is combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Brentuximab vedotin can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Brentuximab vedotin can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Brentuximab vedotin can be decreased when combined with Bosutinib.]
[L04AA31, teriflunomide, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Teriflunomide.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Abetimus is combined with Brentuximab vedotin.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Aldosterone is combined with Brentuximab vedotin.]
[L01EX05, regorafenib, The serum concentration of Brentuximab vedotin can be increased when it is combined with Regorafenib.]
[N05CA04, barbital, The metabolism of Brentuximab vedotin can be increased when combined with Barbital.]
[J05AE04, nelfinavir, The metabolism of Brentuximab vedotin can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The risk or severity of adverse effects can be increased when Bendamustine is combined with Brentuximab vedotin.]
[N03AX22, perampanel, The metabolism of Brentuximab vedotin can be increased when combined with Perampanel.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Brentuximab vedotin.]
[H01CB05, pasireotide, The metabolism of Brentuximab vedotin can be decreased when combined with Pasireotide.]
[G04BE03, sildenafil, The serum concentration of Brentuximab vedotin can be increased when it is combined with Sildenafil.]
[L01EA05, ponatinib, The serum concentration of Brentuximab vedotin can be increased when it is combined with Ponatinib.]
[B01AF02, apixaban, The serum concentration of Brentuximab vedotin can be increased when it is combined with Apixaban.]
[C10AX12, lomitapide, The serum concentration of Brentuximab vedotin can be increased when it is combined with Lomitapide.]
[J06BC02, raxibacumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Raxibacumab.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Brentuximab vedotin can be increased when combined with Glycerol phenylbutyrate.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be decreased when combined with Brentuximab vedotin.]
[A10BK02, canagliflozin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Canagliflozin.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Dimethyl fumarate.]
[A06AX06, tegaserod, The serum concentration of Brentuximab vedotin can be increased when it is combined with Tegaserod.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Benzocaine.]
[L04AA18, everolimus, The serum concentration of Brentuximab vedotin can be increased when it is combined with Everolimus.]
[L01EC02, dabrafenib, The serum concentration of Brentuximab vedotin can be decreased when it is combined with Dabrafenib.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Benzyl alcohol.]
[L01EB03, afatinib, The serum concentration of Brentuximab vedotin can be increased when it is combined with Afatinib.]
[J05AJ03, dolutegravir, The serum concentration of Brentuximab vedotin can be increased when it is combined with Dolutegravir.]
[C02KX05, riociguat, The serum concentration of Brentuximab vedotin can be increased when it is combined with Riociguat.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Brentuximab vedotin.]
[N03AF04, eslicarbazepine, The metabolism of Brentuximab vedotin can be increased when combined with Eslicarbazepine.]
[J05AP05, simeprevir, The serum concentration of Brentuximab vedotin can be increased when it is combined with Simeprevir.]
[J05AP08, sofosbuvir, The serum concentration of Brentuximab vedotin can be increased when it is combined with Sofosbuvir.]
[N05CH03, tasimelteon, The metabolism of Brentuximab vedotin can be decreased when combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Brentuximab vedotin can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Brentuximab vedotin can be increased when combined with Apremilast.]
[L02BG02, formestane, The metabolism of Brentuximab vedotin can be increased when combined with Formestane.]
[S03BA03, betamethasone, The metabolism of Brentuximab vedotin can be increased when combined with Betamethasone.]
[L04AC11, siltuximab, The metabolism of Brentuximab vedotin can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Brentuximab vedotin can be decreased when combined with Ceritinib.]
[L01FG02, ramucirumab, The risk or severity of adverse effects can be increased when Ramucirumab is combined with Brentuximab vedotin.]
[B01AC26, vorapaxar, The serum concentration of Brentuximab vedotin can be increased when it is combined with Vorapaxar.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Vedolizumab.]
[B01AA07, acenocoumarol, The serum concentration of Acenocoumarol can be increased when it is combined with Brentuximab vedotin.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Belinostat is combined with Brentuximab vedotin.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be decreased when combined with Brentuximab vedotin.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Peginterferon beta-1a.]
[N05CM19, suvorexant, The serum concentration of Brentuximab vedotin can be increased when it is combined with Suvorexant.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Brentuximab vedotin.]
[L01FF02, pembrolizumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Pembrolizumab.]
[J01XA05, oritavancin, The metabolism of Brentuximab vedotin can be increased when combined with Oritavancin.]
[A10BJ05, dulaglutide, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Dulaglutide.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Decitabine is combined with Brentuximab vedotin.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Pirfenidone is combined with Brentuximab vedotin.]
[L01EX09, nintedanib, The metabolism of Brentuximab vedotin can be decreased when combined with Nintedanib.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Blinatumomab.]
[J05AP09, dasabuvir, The serum concentration of Brentuximab vedotin can be increased when it is combined with Dasabuvir.]
[L01XK01, olaparib, The metabolism of Brentuximab vedotin can be decreased when combined with Olaparib.]
[L01FF01, nivolumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Nivolumab.]
[B01AF03, edoxaban, The serum concentration of Brentuximab vedotin can be increased when it is combined with Edoxaban.]
[N06AX11, mirtazapine, The metabolism of Brentuximab vedotin can be decreased when combined with Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Brentuximab vedotin can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The serum concentration of Brentuximab vedotin can be increased when it is combined with Palbociclib.]
[L01EX08, lenvatinib, The serum concentration of Brentuximab vedotin can be increased when it is combined with Lenvatinib.]
[L01XH03, panobinostat, The metabolism of Panobinostat can be decreased when combined with Brentuximab vedotin.]
[J05AP07, daclatasvir, The serum concentration of Brentuximab vedotin can be increased when it is combined with Daclatasvir.]
[N02BE01, acetaminophen, The metabolism of Brentuximab vedotin can be increased when combined with Acetaminophen.]
[L01DC01, bleomycin, The risk or severity of pulmonary toxicity can be increased when Brentuximab vedotin is combined with Bleomycin.]
[J05AP06, asunaprevir, The serum concentration of Brentuximab vedotin can be increased when it is combined with Asunaprevir.]
[C10AX14, alirocumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Alirocumab.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be decreased when combined with Brentuximab vedotin.]
[A04AD14, rolapitant, The serum concentration of Brentuximab vedotin can be increased when it is combined with Rolapitant.]
[G02CX02, flibanserin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Flibanserin.]
[C10AX13, evolocumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Evolocumab.]
[S01EC01, acetazolamide, The metabolism of Brentuximab vedotin can be decreased when combined with Acetazolamide.]
[V03AB37, idarucizumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Idarucizumab.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Brentuximab vedotin.]
[A16AB13, asfotase alfa, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Asfotase alfa.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Mepolizumab is combined with Brentuximab vedotin.]
[J02AC05, isavuconazole, The serum concentration of Brentuximab vedotin can be increased when it is combined with Isavuconazole.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be decreased when combined with Brentuximab vedotin.]
[J05AF13, tenofovir alafenamide, The metabolism of Brentuximab vedotin can be decreased when combined with Tenofovir alafenamide.]
[L01FC01, daratumumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Daratumumab.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be decreased when combined with Brentuximab vedotin.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be decreased when combined with Brentuximab vedotin.]
[L01FE03, necitumumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Necitumumab.]
[L01FX08, elotuzumab, The risk or severity of adverse effects can be increased when Elotuzumab is combined with Brentuximab vedotin.]
[L01ED03, alectinib, The metabolism of Alectinib can be decreased when combined with Brentuximab vedotin.]
[J06BB02, tetanus immune globulin, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tetanus immune globulin, human.]
[B01AC27, selexipag, The serum concentration of Brentuximab vedotin can be increased when it is combined with Selexipag.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Brentuximab vedotin.]
[M04AB05, lesinurad, The metabolism of Brentuximab vedotin can be increased when combined with Lesinurad.]
[J05AP10, elbasvir, The serum concentration of Brentuximab vedotin can be increased when it is combined with Elbasvir.]
[J05AP11, grazoprevir, The serum concentration of Brentuximab vedotin can be increased when it is combined with Grazoprevir.]
[N05CA05, aprobarbital, The metabolism of Brentuximab vedotin can be increased when combined with Aprobarbital.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Ixekizumab.]
[R03DX08, reslizumab, The risk or severity of adverse effects can be increased when Reslizumab is combined with Brentuximab vedotin.]
[J06BC04, obiltoxaximab, The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Brentuximab vedotin.]
[L01XX52, venetoclax, The serum concentration of Brentuximab vedotin can be increased when it is combined with Venetoclax.]
[N05AX17, pimavanserin, The metabolism of Brentuximab vedotin can be decreased when combined with Pimavanserin.]
[L01FF05, atezolizumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Atezolizumab.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Bupivacaine.]
[N07BC01, buprenorphine, The metabolism of Brentuximab vedotin can be decreased when combined with Buprenorphine.]
[L01AB01, busulfan, The metabolism of Busulfan can be decreased when combined with Brentuximab vedotin.]
[L01XX27, arsenic trioxide, The serum concentration of Brentuximab vedotin can be increased when it is combined with Arsenic trioxide.]
[J06BC03, bezlotoxumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Bezlotoxumab.]
[L01FX10, olaratumab, The risk or severity of adverse effects can be increased when Olaratumab is combined with Brentuximab vedotin.]
[L01XK03, rucaparib, The metabolism of Brentuximab vedotin can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The metabolism of Brentuximab vedotin can be decreased when combined with Azithromycin.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Brodalumab.]
[L01EF02, ribociclib, The metabolism of Brentuximab vedotin can be decreased when combined with Ribociclib.]
[L01FF04, avelumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Avelumab.]
[L04AA36, ocrelizumab, Ocrelizumab may increase the immunosuppressive activities of Brentuximab vedotin.]
[D11AH05, dupilumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Dupilumab.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Oxybuprocaine.]
[D05AX03, calcitriol, The metabolism of Brentuximab vedotin can be increased when combined with Calcitriol.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Brentuximab vedotin.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Brentuximab vedotin.]
[J05AE09, tipranavir, The serum concentration of Brentuximab vedotin can be increased when it is combined with Tipranavir.]
[L04AB02, infliximab, The metabolism of Brentuximab vedotin can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Brentuximab vedotin can be decreased when combined with Midostaurin.]
[L01FF03, durvalumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Durvalumab.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Brentuximab vedotin.]
[L04AC14, sarilumab, The metabolism of Brentuximab vedotin can be increased when combined with Sarilumab.]
[B01AF04, betrixaban, The serum concentration of Brentuximab vedotin can be increased when it is combined with Betrixaban.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Guselkumab.]
[D01AC10, bifonazole, The metabolism of Brentuximab vedotin can be decreased when combined with Bifonazole.]
[L01BC06, capecitabine, The risk or severity of adverse effects can be increased when Capecitabine is combined with Brentuximab vedotin.]
[L01XX59, enasidenib, The serum concentration of Brentuximab vedotin can be increased when it is combined with Enasidenib.]
[L01EH02, neratinib, The serum concentration of Brentuximab vedotin can be increased when it is combined with Neratinib.]
[J06BD01, palivizumab, The risk or severity of adverse effects can be increased when Palivizumab is combined with Brentuximab vedotin.]
[L01FB01, inotuzumab ozogamicin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Inotuzumab ozogamicin.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Vorinostat is combined with Brentuximab vedotin.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Brentuximab vedotin.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be decreased when combined with Brentuximab vedotin.]
[C07AB07, bisoprolol, The serum concentration of Brentuximab vedotin can be increased when it is combined with Bisoprolol.]
[J05AG03, efavirenz, The metabolism of Brentuximab vedotin can be decreased when combined with Efavirenz.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Brentuximab vedotin.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Brentuximab vedotin.]
[R03BA02, budesonide, The metabolism of Brentuximab vedotin can be increased when combined with Budesonide.]
[L01EL02, acalabrutinib, The metabolism of Brentuximab vedotin can be decreased when combined with Acalabrutinib.]
[J05AX18, letermovir, The metabolism of Brentuximab vedotin can be decreased when combined with Letermovir.]
[R03DX10, benralizumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Benralizumab.]
[B02BX06, emicizumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Emicizumab.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Capsaicin.]
[A10BK04, ertugliflozin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Ertugliflozin.]
[L02BB05, apalutamide, The serum concentration of Brentuximab vedotin can be decreased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Brentuximab vedotin can be increased when combined with Carbamazepine.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Brentuximab vedotin.]
[C07AG02, carvedilol, The serum concentration of Brentuximab vedotin can be increased when it is combined with Carvedilol.]
[J05AX23, ibalizumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Ibalizumab.]
[M05BX05, burosumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Burosumab.]
[B02BX09, fostamatinib, The metabolism of Brentuximab vedotin can be decreased when combined with Fostamatinib.]
[N03AX24, cannabidiol, The metabolism of Brentuximab vedotin can be decreased when combined with Cannabidiol.]
[N02CD01, erenumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Erenumab.]
[B02BX08, avatrombopag, The serum concentration of Brentuximab vedotin can be increased when it is combined with Avatrombopag.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Baricitinib.]
[H01CC03, elagolix, The serum concentration of Brentuximab vedotin can be increased when it is combined with Elagolix.]
[L01XX62, ivosidenib, The metabolism of Brentuximab vedotin can be increased when combined with Ivosidenib.]
[L04AC17, tildrakizumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tildrakizumab.]
[L01FX09, mogamulizumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Mogamulizumab.]
[N03AX17, stiripentol, The metabolism of Brentuximab vedotin can be decreased when combined with Stiripentol.]
[B02BX07, lusutrombopag, The serum concentration of Brentuximab vedotin can be increased when it is combined with Lusutrombopag.]
[J05AX24, tecovirimat, The metabolism of Brentuximab vedotin can be increased when combined with Tecovirimat.]
[B06AC05, lanadelumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Lanadelumab.]
[N02CD03, fremanezumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Fremanezumab.]
[L01EM04, duvelisib, The metabolism of Brentuximab vedotin can be decreased when combined with Duvelisib.]
[L01FF06, cemiplimab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Cemiplimab.]
[N02CD02, galcanezumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Galcanezumab.]
[L01EB07, dacomitinib, The serum concentration of Brentuximab vedotin can be increased when it is combined with Dacomitinib.]
[J01AA14, sarecycline, The serum concentration of Brentuximab vedotin can be increased when it is combined with Sarecycline.]
[J01AA15, omadacycline, The serum concentration of Brentuximab vedotin can be increased when it is combined with Omadacycline.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Chloroprocaine.]
[L01XK04, talazoparib, The serum concentration of Brentuximab vedotin can be increased when it is combined with Talazoparib.]
[R03BB08, revefenacin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Revefenacin.]
[L01ED05, lorlatinib, The serum concentration of Brentuximab vedotin can be decreased when it is combined with Lorlatinib.]
[L04AA39, emapalumab, The metabolism of Brentuximab vedotin can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Brentuximab vedotin.]
[L01EX12, larotrectinib, The serum concentration of Brentuximab vedotin can be increased when it is combined with Larotrectinib.]
[L01EX13, gilteritinib, The metabolism of Brentuximab vedotin can be decreased when combined with Gilteritinib.]
[L01XJ03, glasdegib, The serum concentration of Brentuximab vedotin can be increased when it is combined with Glasdegib.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Ravulizumab.]
[A06AX05, prucalopride, The metabolism of Prucalopride can be decreased when combined with Brentuximab vedotin.]
[B01AX07, caplacizumab, The risk or severity of adverse effects can be increased when Caplacizumab is combined with Brentuximab vedotin.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Brentuximab vedotin.]
[P02BX04, triclabendazole, The metabolism of Brentuximab vedotin can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The metabolism of Brentuximab vedotin can be increased when combined with Esketamine.]
[L04AA42, siponimod, The metabolism of Siponimod can be decreased when combined with Brentuximab vedotin.]
[J01FA09, clarithromycin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Clarithromycin.]
[L01EN01, erdafitinib, The serum concentration of Brentuximab vedotin can be increased when it is combined with Erdafitinib.]
[M05BX06, romosozumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Romosozumab.]
[N05BA09, clobazam, The metabolism of Brentuximab vedotin can be increased when combined with Clobazam.]
[H02AB14, cloprednol, The metabolism of Brentuximab vedotin can be increased when combined with Cloprednol.]
[L04AB01, etanercept, The metabolism of Brentuximab vedotin can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The metabolism of Brentuximab vedotin can be increased when combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Risankizumab.]
[L01EM03, alpelisib, The metabolism of Brentuximab vedotin can be increased when combined with Alpelisib.]
[L01FX14, polatuzumab vedotin, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Polatuzumab vedotin.]
[L02BB06, darolutamide, The serum concentration of Brentuximab vedotin can be increased when it is combined with Darolutamide.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be decreased when combined with Brentuximab vedotin.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Upadacitinib.]
[L01EJ02, fedratinib, The serum concentration of Brentuximab vedotin can be increased when it is combined with Fedratinib.]
[L01EX14, entrectinib, The serum concentration of Brentuximab vedotin can be increased when it is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Brentuximab vedotin can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Brentuximab vedotin can be decreased when combined with Pretomanid.]
[J01XX12, lefamulin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Lefamulin.]
[N04CX01, istradefylline, The serum concentration of Brentuximab vedotin can be increased when it is combined with Istradefylline.]
[S01LA06, brolucizumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Brolucizumab.]
[J01XX09, daptomycin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Daptomycin.]
[J01DB01, cephalexin, The metabolism of Brentuximab vedotin can be decreased when combined with Cephalexin.]
[J01DB09, cephradine, The metabolism of Brentuximab vedotin can be increased when combined with Cefradine.]
[H02AB13, deflazacort, The metabolism of Brentuximab vedotin can be increased when combined with Deflazacort.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Brentuximab vedotin.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Brentuximab vedotin.]
[L01FD04, trastuzumab deruxtecan, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Trastuzumab deruxtecan.]
[N02CC08, lasmiditan, The serum concentration of Brentuximab vedotin can be increased when it is combined with Lasmiditan.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Diroximel fumarate.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Brentuximab vedotin.]
[B06AX03, voxelotor, The serum concentration of Brentuximab vedotin can be increased when it is combined with Voxelotor.]
[N03AX25, cenobamate, The serum concentration of Brentuximab vedotin can be decreased when it is combined with Cenobamate.]
[N02CD04, ubrogepant, The serum concentration of Brentuximab vedotin can be increased when it is combined with Ubrogepant.]
[L01FX13, enfortumab vedotin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Enfortumab vedotin.]
[N05CM21, lemborexant, The serum concentration of Brentuximab vedotin can be increased when it is combined with Lemborexant.]
[L01XX72, tazemetostat, The metabolism of Brentuximab vedotin can be decreased when combined with Tazemetostat.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Teprotumumab is combined with Brentuximab vedotin.]
[L01FC02, isatuximab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Isatuximab.]
[N02CD06, rimegepant, The serum concentration of Brentuximab vedotin can be increased when it is combined with Rimegepant.]
[N02CD05, eptinezumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Eptinezumab.]
[J05AB16, remdesivir, The metabolism of Brentuximab vedotin can be decreased when combined with Remdesivir.]
[H02CA02, osilodrostat, The metabolism of Brentuximab vedotin can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Brentuximab vedotin can be decreased when combined with Amprenavir.]
[L04AA38, ozanimod, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Ozanimod.]
[L01EE04, selumetinib, The serum concentration of Brentuximab vedotin can be increased when it is combined with Selumetinib.]
[M01AH02, rofecoxib, The metabolism of Brentuximab vedotin can be increased when combined with Rofecoxib.]
[L01XF03, bexarotene, The metabolism of Brentuximab vedotin can be increased when combined with Bexarotene.]
[C08CA16, clevidipine, The metabolism of Brentuximab vedotin can be increased when combined with Clevidipine.]
[C01BD07, dronedarone, The serum concentration of Brentuximab vedotin can be increased when it is combined with Dronedarone.]
[J01FA13, dirithromycin, The metabolism of Brentuximab vedotin can be decreased when combined with Dirithromycin.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Brentuximab vedotin.]
[S03AA08, chloramphenicol, The metabolism of Brentuximab vedotin can be decreased when combined with Chloramphenicol.]
[L01FX17, sacituzumab govitecan, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Sacituzumab govitecan.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Brentuximab vedotin.]
[L01EX17, capmatinib, The serum concentration of Brentuximab vedotin can be increased when it is combined with Capmatinib.]
[D07XB03, fluprednidene, The metabolism of Brentuximab vedotin can be increased when combined with Fluprednidene.]
[L01EX19, ripretinib, The serum concentration of Brentuximab vedotin can be increased when it is combined with Ripretinib.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Brentuximab vedotin is combined with Inebilizumab.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Dyclonine.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Stepronin is combined with Brentuximab vedotin.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Brentuximab vedotin.]
[R06AX22, ebastine, The metabolism of Brentuximab vedotin can be decreased when combined with Ebastine.]
[J05AX29, fostemsavir, The serum concentration of Brentuximab vedotin can be increased when it is combined with Fostemsavir.]
[L01FX12, tafasitamab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tafasitamab.]
[L01FX15, belantamab mafodotin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Belantamab mafodotin.]
[L04AC19, satralizumab, The serum concentration of Brentuximab vedotin can be decreased when it is combined with Satralizumab.]
[L01EX23, pralsetinib, The serum concentration of Brentuximab vedotin can be increased when it is combined with Pralsetinib.]
[G03CA06, chlorotrianisene, Chlorotrianisene may increase the thrombogenic activities of Brentuximab vedotin.]
[N05AA01, chlorpromazine, The metabolism of Brentuximab vedotin can be increased when combined with Chlorpromazine.]
[B06AC06, berotralstat, The serum concentration of Brentuximab vedotin can be increased when it is combined with Berotralstat.]
[A16AX20, lonafarnib, The serum concentration of Brentuximab vedotin can be increased when it is combined with Lonafarnib.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Fludarabine is combined with Brentuximab vedotin.]
[J06BD04, ansuvimab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Ansuvimab.]
[L02BX04, relugolix, The serum concentration of Brentuximab vedotin can be increased when it is combined with Relugolix.]
[L01FD06, margetuximab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Margetuximab.]
[L04AD03, voclosporin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Voclosporin.]
[P03AX07, abametapir, The serum concentration of Brentuximab vedotin can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The serum concentration of Brentuximab vedotin can be increased when it is combined with Tepotinib.]
[L01EX25, umbralisib, The serum concentration of Brentuximab vedotin can be increased when it is combined with Umbralisib.]
[V03AF12, trilaciclib, The serum concentration of Brentuximab vedotin can be increased when it is combined with Trilaciclib.]
[N03AX10, felbamate, The metabolism of Brentuximab vedotin can be increased when combined with Felbamate.]
[R03BA03, flunisolide, The metabolism of Brentuximab vedotin can be increased when combined with Flunisolide.]
[S02BA08, fluocinolone acetonide, The metabolism of Brentuximab vedotin can be increased when combined with Fluocinolone acetonide.]
[L04AA50, ponesimod, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Ponesimod.]
[S01LA08, bevacizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Brentuximab vedotin.]
[L01EK03, tivozanib, The serum concentration of Brentuximab vedotin can be increased when it is combined with Tivozanib.]
[L03AB10, peginterferon alfa-2b, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Brentuximab vedotin.]
[L01FF07, dostarlimab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Dostarlimab.]
[L01FX22, loncastuximab tesirine, The serum concentration of Brentuximab vedotin can be increased when it is combined with Loncastuximab tesirine.]
[A02BA01, cimetidine, The metabolism of Brentuximab vedotin can be decreased when combined with Cimetidine.]
[L01FX18, amivantamab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Amivantamab.]
[L01XX73, sotorasib, The serum concentration of Brentuximab vedotin can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Brentuximab vedotin can be decreased when combined with Infigratinib.]
[J06BD05, sotrovimab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Sotrovimab.]
[S03AA07, ciprofloxacin, The metabolism of Brentuximab vedotin can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Brentuximab vedotin.]
[N06AB04, citalopram, The metabolism of Brentuximab vedotin can be decreased when combined with Citalopram.]
[N06DX03, aducanumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Aducanumab.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Pegcetacoplan.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Brentuximab vedotin.]
[L04AA48, belumosudil, The serum concentration of Brentuximab vedotin can be increased when it is combined with Belumosudil.]
[P01CA03, fexinidazole, The metabolism of Brentuximab vedotin can be decreased when combined with Fexinidazole.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Anifrolumab.]
[L01XX74, belzutifan, The serum concentration of Brentuximab vedotin can be decreased when it is combined with Belzutifan.]
[L01EB10, mobocertinib, The serum concentration of Brentuximab vedotin can be decreased when it is combined with Mobocertinib.]
[L01FX23, tisotumab vedotin, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tisotumab vedotin.]
[V09GA01, technetium Tc 99m sestamibi, The serum concentration of Brentuximab vedotin can be increased when it is combined with Technetium Tc-99m sestamibi.]
[L04AA59, avacopan, The metabolism of Brentuximab vedotin can be decreased when combined with Avacopan.]
[N06AX25, St. John's wort extract, The serum concentration of Brentuximab vedotin can be decreased when it is combined with St. John's Wort.]
[L01EA06, asciminib, The serum concentration of Brentuximab vedotin can be increased when it is combined with Asciminib.]
[J05AX10, maribavir, The serum concentration of Brentuximab vedotin can be increased when it is combined with Maribavir.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Ropeginterferon alfa-2b.]
[R03DX11, tezepelumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tezepelumab.]
[D11AH07, tralokinumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tralokinumab.]
[L04AA55, sutimlimab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Sutimlimab.]
[D11AH08, abrocitinib, The serum concentration of Brentuximab vedotin can be increased when it is combined with Abrocitinib.]
[J04BA01, clofazimine, The serum concentration of Brentuximab vedotin can be increased when it is combined with Clofazimine.]
[C10AB01, clofibrate, The metabolism of Brentuximab vedotin can be increased when combined with Clofibrate.]
[B06AX04, mitapivat, The metabolism of Brentuximab vedotin can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The serum concentration of Brentuximab vedotin can be increased when it is combined with Pacritinib.]
[G03GB02, clomiphene, The serum concentration of Brentuximab vedotin can be increased when it is combined with Clomifene.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Brentuximab vedotin.]
[S01EA04, clonidine, The metabolism of Clonidine can be decreased when combined with Brentuximab vedotin.]
[C01EB24, mavacamten, The serum concentration of Brentuximab vedotin can be decreased when it is combined with Mavacamten.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Deucravacitinib.]
[L01FX20, tremelimumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tremelimumab.]
[J05AX31, lenacapavir, The metabolism of Brentuximab vedotin can be decreased when combined with Lenacapavir.]
[N05AH02, clozapine, The metabolism of Brentuximab vedotin can be increased when combined with Clozapine.]
[L04AA57, ublituximab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Ublituximab.]
[L01EN04, futibatinib, The serum concentration of Brentuximab vedotin can be increased when it is combined with Futibatinib.]
[L01FE02, panitumumab, The risk or severity of adverse effects can be increased when Panitumumab is combined with Brentuximab vedotin.]
[A10BK06, sotagliflozin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Sotagliflozin.]
[H01AC08, somatrogon, The metabolism of Brentuximab vedotin can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Cocaine.]
[L04AC21, bimekizumab, The metabolism of Brentuximab vedotin can be increased when combined with Bimekizumab.]
[J06BB04, hepatitis B immune globulin, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Brentuximab vedotin.]
[M04AC01, colchicine, The metabolism of Colchicine can be decreased when combined with Brentuximab vedotin.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Leflunomide.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Nelarabine is combined with Brentuximab vedotin.]
[J01FA15, telithromycin, The metabolism of Brentuximab vedotin can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Ciclesonide is combined with Brentuximab vedotin.]
[J02AC02, itraconazole, The serum concentration of Brentuximab vedotin can be increased when it is combined with Itraconazole.]
[N05BA10, ketazolam, The metabolism of Brentuximab vedotin can be decreased when combined with Ketazolam.]
[L01EA01, imatinib, The serum concentration of Brentuximab vedotin can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Brentuximab vedotin can be decreased when combined with Posaconazole.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Brentuximab vedotin.]
[S01BA03, cortisone, The metabolism of Brentuximab vedotin can be increased when combined with Cortisone.]
[C08CA11, manidipine, The metabolism of Brentuximab vedotin can be decreased when combined with Manidipine.]
[H02AB15, meprednisone, The metabolism of Brentuximab vedotin can be increased when combined with Meprednisone.]
[R06AD07, mequitazine, The metabolism of Brentuximab vedotin can be decreased when combined with Mequitazine.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Brentuximab vedotin.]
[J01FA03, midecamycin, The metabolism of Brentuximab vedotin can be decreased when combined with Midecamycin.]
[J05AF07, tenofovir disoproxil, The serum concentration of Brentuximab vedotin can be increased when it is combined with Tenofovir disoproxil.]
[L01AA01, cyclophosphamide, The metabolism of Brentuximab vedotin can be increased when combined with Cyclophosphamide.]
[S01XA18, cyclosporine, Brentuximab vedotin may increase the immunosuppressive activities of Cyclosporine.]
[N06BA07, modafinil, The metabolism of Brentuximab vedotin can be increased when combined with Modafinil.]
[C10AA07, rosuvastatin, The metabolism of Brentuximab vedotin can be decreased when combined with Rosuvastatin.]
[C03XA02, conivaptan, The serum concentration of Brentuximab vedotin can be increased when it is combined with Conivaptan.]
[R03DX05, omalizumab, The risk or severity of adverse effects can be increased when Omalizumab is combined with Brentuximab vedotin.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Brentuximab vedotin.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Brentuximab vedotin.]
[M01AH05, etoricoxib, The metabolism of Brentuximab vedotin can be decreased when combined with Etoricoxib.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Dacarbazine is combined with Brentuximab vedotin.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Dactinomycin is combined with Brentuximab vedotin.]
[G03XA01, danazol, The metabolism of Brentuximab vedotin can be decreased when combined with Danazol.]
[L01DB02, daunorubicin, The metabolism of Brentuximab vedotin can be decreased when combined with Daunorubicin.]
[N06AX06, nefazodone, The metabolism of Brentuximab vedotin can be decreased when combined with Nefazodone.]
[L01FE01, cetuximab, The risk or severity of adverse effects can be increased when Cetuximab is combined with Brentuximab vedotin.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Brentuximab vedotin.]
[N06AA01, desipramine, The metabolism of Brentuximab vedotin can be decreased when combined with Desipramine.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Desoximetasone is combined with Brentuximab vedotin.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Brentuximab vedotin.]
[N03AF02, oxcarbazepine, The metabolism of Brentuximab vedotin can be increased when combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The metabolism of Brentuximab vedotin can be increased when combined with Dexamethasone.]
[G04BD04, oxybutynin, The metabolism of Brentuximab vedotin can be decreased when combined with Oxybutynin.]
[L04AB04, adalimumab, The metabolism of Brentuximab vedotin can be increased when combined with Adalimumab.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Cinchocaine.]
[J01CF01, dicloxacillin, The metabolism of Brentuximab vedotin can be increased when combined with Dicloxacillin.]
[G03CC02, dienestrol, Dienestrol may increase the thrombogenic activities of Brentuximab vedotin.]
[L01DC04, ixabepilone, The serum concentration of Brentuximab vedotin can be increased when it is combined with Ixabepilone.]
[L01EB02, erlotinib, The metabolism of Brentuximab vedotin can be decreased when combined with Erlotinib.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Pirarubicin.]
[L02AA01, diethylstilbestrol, The metabolism of Brentuximab vedotin can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The metabolism of Brentuximab vedotin can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The metabolism of Brentuximab vedotin can be increased when combined with Difluocortolone.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be decreased when combined with Brentuximab vedotin.]
[C01AA05, digoxin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Digoxin.]
[L02AA02, polyestradiol phosphate, Polyestradiol phosphate may increase the thrombogenic activities of Brentuximab vedotin.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Brentuximab vedotin.]
[C04AE04, dihydroergocristine, The metabolism of Brentuximab vedotin can be decreased when combined with Dihydroergocristine.]
[N02CA01, dihydroergotamine, The metabolism of Brentuximab vedotin can be decreased when combined with Dihydroergotamine.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Brentuximab vedotin.]
[J05AE08, atazanavir, The metabolism of Brentuximab vedotin can be decreased when combined with Atazanavir.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Brentuximab vedotin can be decreased when combined with Diltiazem.]
[M02AX03, dimethyl sulfoxide, The metabolism of Brentuximab vedotin can be decreased when combined with Dimethyl sulfoxide.]
[G03CA09, promestriene, Promestriene may increase the thrombogenic activities of Brentuximab vedotin.]
[C05CA03, diosmin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Diosmin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Diphenhydramine.]
[A03FA02, cisapride, The metabolism of Brentuximab vedotin can be decreased when combined with Cisapride.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be decreased when combined with Brentuximab vedotin.]
[J06BB01, Rho(D) immune globulin, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Human Rho(D) immune globulin.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Natalizumab.]
[S02AA12, rifamycin SV, The serum concentration of Brentuximab vedotin can be increased when it is combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Brentuximab vedotin can be increased when combined with Rifapentine.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Brentuximab vedotin.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Ropivacaine.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be decreased when combined with Brentuximab vedotin.]
[A04AD12, aprepitant, The metabolism of Brentuximab vedotin can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be decreased when combined with Brentuximab vedotin.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be decreased when combined with Brentuximab vedotin.]
[J05AE07, fosamprenavir, The metabolism of Brentuximab vedotin can be decreased when combined with Fosamprenavir.]
[C02KX02, ambrisentan, The serum concentration of Brentuximab vedotin can be increased when it is combined with Ambrisentan.]
[C01EB18, ranolazine, The serum concentration of Brentuximab vedotin can be increased when it is combined with Ranolazine.]
[L01DB01, doxorubicin, The metabolism of Brentuximab vedotin can be decreased when combined with Doxorubicin.]
[C10AA01, simvastatin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Simvastatin.]
[C07AB13, talinolol, The serum concentration of Brentuximab vedotin can be increased when it is combined with Talinolol.]
[H01AA01, corticotropin, The metabolism of Brentuximab vedotin can be increased when combined with Corticotropin.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Temozolomide is combined with Brentuximab vedotin.]
[D01BA02, terbinafine, The metabolism of Brentuximab vedotin can be increased when combined with Terbinafine.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be decreased when combined with Brentuximab vedotin.]
[G03CX01, tibolone, Tibolone may increase the thrombogenic activities of Brentuximab vedotin.]
[N03AX11, topiramate, The metabolism of Brentuximab vedotin can be increased when combined with Topiramate.]
[L02BA02, toremifene, The serum concentration of Brentuximab vedotin can be increased when it is combined with Toremifene.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Trilostane is combined with Brentuximab vedotin.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Trofosfamide.]
[J06BB03, varicella-zoster immune globulin, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Human varicella-zoster immune globulin.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be decreased when combined with Brentuximab vedotin.]
[C08CA12, mepirodipine, The metabolism of Brentuximab vedotin can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The metabolism of Brentuximab vedotin can be decreased when combined with Epinephrine.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Brentuximab vedotin.]
[N03AX15, zonisamide, The serum concentration of Brentuximab vedotin can be increased when it is combined with Zonisamide.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Brentuximab vedotin.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Brentuximab vedotin.]
[N02CA02, ergotamine, The metabolism of Brentuximab vedotin can be decreased when combined with Ergotamine.]
[S01AA17, erythromycin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Erythromycin.]
[G03CA03, estradiol, Estradiol may increase the thrombogenic activities of Brentuximab vedotin.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Estramustine is combined with Brentuximab vedotin.]
[G03CC06, estriol, Estriol may increase the thrombogenic activities of Brentuximab vedotin.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may increase the thrombogenic activities of Brentuximab vedotin.]
[G03CC04, estrone, Estrone may increase the thrombogenic activities of Brentuximab vedotin.]
[J04AK02, ethambutol, The metabolism of Brentuximab vedotin can be decreased when combined with Ethambutol.]
[R03BA09, fluticasone furoate, The metabolism of Brentuximab vedotin can be increased when combined with Fluticasone furoate.]
[R03BA05, fluticasone, The metabolism of Brentuximab vedotin can be increased when combined with Fluticasone.]
[L02AA03, ethinyl estradiol, Ethinylestradiol may increase the thrombogenic activities of Brentuximab vedotin.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Etidocaine.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Brentuximab vedotin.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Brentuximab vedotin.]
[R06AX11, astemizole, The metabolism of Brentuximab vedotin can be decreased when combined with Astemizole.]
[R06AX12, terfenadine, The metabolism of Brentuximab vedotin can be decreased when combined with Terfenadine.]
[N06AB08, fluvoxamine, The metabolism of Brentuximab vedotin can be decreased when combined with Fluvoxamine.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Brentuximab vedotin.]
[C10AA03, pravastatin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Pravastatin.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Brentuximab vedotin.]
[P02CA03, albendazole, The metabolism of Brentuximab vedotin can be decreased when combined with Albendazole.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Brentuximab vedotin.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Brentuximab vedotin.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Brentuximab vedotin.]
[J01CF05, floxacillin, The metabolism of Brentuximab vedotin can be increased when combined with Flucloxacillin.]
[J02AC01, fluconazole, The serum concentration of Brentuximab vedotin can be increased when it is combined with Fluconazole.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Flucytosine is combined with Brentuximab vedotin.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Brentuximab vedotin.]
[D07AC08, fluocinonide, The metabolism of Brentuximab vedotin can be increased when combined with Fluocinonide.]
[H02AB03, fluocortolone, The metabolism of Brentuximab vedotin can be increased when combined with Fluocortolone.]
[V03AZ01, ethanol, The metabolism of Brentuximab vedotin can be increased when combined with Ethanol.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Floxuridine is combined with Brentuximab vedotin.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Brentuximab vedotin.]
[L01BC02, fluorouracil, The risk or severity of adverse effects can be increased when Fluorouracil is combined with Brentuximab vedotin.]
[N06AB03, fluoxetine, The metabolism of Brentuximab vedotin can be decreased when combined with Fluoxetine.]
[J05AE10, darunavir, The serum concentration of Brentuximab vedotin can be increased when it is combined with Darunavir.]
[N05CF04, eszopiclone, The metabolism of Eszopiclone can be decreased when combined with Brentuximab vedotin.]
[N03AA04, barbexaclone, The metabolism of Brentuximab vedotin can be increased when combined with Barbexaclone.]
[L01EA02, dasatinib, The metabolism of Brentuximab vedotin can be decreased when combined with Dasatinib.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be decreased when combined with Brentuximab vedotin.]
[J05AG04, etravirine, The metabolism of Brentuximab vedotin can be increased when combined with Etravirine.]
[L01EH01, lapatinib, The serum concentration of Brentuximab vedotin can be increased when it is combined with Lapatinib.]
[A10BB01, glyburide, The metabolism of Brentuximab vedotin can be decreased when combined with Glyburide.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be decreased when combined with Brentuximab vedotin.]
[C02CA04, doxazosin, The metabolism of Brentuximab vedotin can be decreased when combined with Doxazosin.]
[L01EX02, sorafenib, The serum concentration of Brentuximab vedotin can be increased when it is combined with Sorafenib.]
[D01BA01, griseofulvin, The metabolism of Brentuximab vedotin can be increased when combined with Griseofulvin.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Brentuximab vedotin.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be decreased when combined with Brentuximab vedotin.]
[C09CA01, losartan, The metabolism of Brentuximab vedotin can be decreased when combined with Losartan.]
[G03DC01, allylestrenol, The metabolism of Brentuximab vedotin can be decreased when combined with Allylestrenol.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Brentuximab vedotin.]
[C08CA10, nilvadipine, The metabolism of Brentuximab vedotin can be decreased when combined with Nilvadipine.]
[C02DB02, hydralazine, The metabolism of Brentuximab vedotin can be decreased when combined with Hydralazine.]
[S02BA01, hydrocortisone, The metabolism of Brentuximab vedotin can be increased when combined with Hydrocortisone.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Brentuximab vedotin.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Brentuximab vedotin.]
[J04AB04, rifabutin, The metabolism of Brentuximab vedotin can be increased when combined with Rifabutin.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Idarubicin is combined with Brentuximab vedotin.]
[L01AA06, ifosfamide, The metabolism of Brentuximab vedotin can be increased when combined with Ifosfamide.]
[L01CD01, paclitaxel, The metabolism of Brentuximab vedotin can be increased when combined with Paclitaxel.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tixocortol.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Topotecan is combined with Brentuximab vedotin.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Brentuximab vedotin.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Brentuximab vedotin.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Brentuximab vedotin.]
[N06AX17, milnacipran, The metabolism of Brentuximab vedotin can be decreased when combined with Milnacipran.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Eculizumab is combined with Brentuximab vedotin.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Articaine.]
[A10BH01, sitagliptin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Sitagliptin.]
[S01LA04, ranibizumab, The risk or severity of adverse effects can be increased when Ranibizumab is combined with Brentuximab vedotin.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Brentuximab vedotin.]
[C10AA06, cerivastatin, The metabolism of Brentuximab vedotin can be increased when combined with Cerivastatin.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Brentuximab vedotin.]
[J04AC01, isoniazid, The metabolism of Brentuximab vedotin can be decreased when combined with Isoniazid.]
[L04AC07, tocilizumab, The metabolism of Brentuximab vedotin can be increased when combined with Tocilizumab.]
[J02AB02, ketoconazole, The serum concentration of Brentuximab vedotin can be increased when it is combined with Ketoconazole.]
[H02CA04, levoketoconazole, The serum concentration of Brentuximab vedotin can be increased when it is combined with Levoketoconazole.]
[V03AC03, deferasirox, The metabolism of Brentuximab vedotin can be increased when combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Brentuximab vedotin can be increased when combined with Abatacept.]
[N03AX18, lacosamide, The metabolism of Brentuximab vedotin can be decreased when combined with Lacosamide.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Brentuximab vedotin.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Lidocaine.]
[N06BA13, armodafinil, The metabolism of Brentuximab vedotin can be increased when combined with Armodafinil.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Brentuximab vedotin.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Lomustine is combined with Brentuximab vedotin.]
[A07DA03, loperamide, The serum concentration of Brentuximab vedotin can be increased when it is combined with Loperamide.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Brentuximab vedotin.]
[N05AH01, loxapine, The serum concentration of Brentuximab vedotin can be increased when it is combined with Loxapine.]
[L01EG01, temsirolimus, The serum concentration of Brentuximab vedotin can be increased when it is combined with Temsirolimus.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Pralatrexate is combined with Brentuximab vedotin.]
[L01EA03, nilotinib, The serum concentration of Brentuximab vedotin can be increased when it is combined with Nilotinib.]
[V04CX04, mannitol, The serum concentration of Brentuximab vedotin can be increased when it is combined with Mannitol.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Brentuximab vedotin.]
[P01BC02, mefloquine, The serum concentration of Brentuximab vedotin can be increased when it is combined with Mefloquine.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Melphalan is combined with Brentuximab vedotin.]
[N02AB02, meperidine, The metabolism of Brentuximab vedotin can be decreased when combined with Meperidine.]
[N03AA01, mephobarbital, The metabolism of Brentuximab vedotin can be increased when combined with Methylphenobarbital.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Mepivacaine.]
[L02BG01, aminoglutethimide, The metabolism of Brentuximab vedotin can be increased when combined with Aminoglutethimide.]
[N05AX13, paliperidone, The serum concentration of Brentuximab vedotin can be increased when it is combined with Paliperidone.]
[H01CB03, lanreotide, The metabolism of Brentuximab vedotin can be decreased when combined with Lanreotide.]
[N07BC02, methadone, The metabolism of Brentuximab vedotin can be decreased when combined with Methadone.]
[H03BB02, methimazole, The metabolism of Brentuximab vedotin can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Pemetrexed is combined with Brentuximab vedotin.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be decreased when combined with Brentuximab vedotin.]
[V04CG05, methylene blue, The serum concentration of Brentuximab vedotin can be increased when it is combined with Methylene blue.]
[G02AB01, methylergonovine, The metabolism of Brentuximab vedotin can be decreased when combined with Methylergometrine.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Brentuximab vedotin.]
[H02AB04, methylprednisolone, The metabolism of Brentuximab vedotin can be increased when combined with Methylprednisolone.]
[N03AF03, rufinamide, The metabolism of Brentuximab vedotin can be increased when combined with Rufinamide.]
[N02CA04, methysergide, The metabolism of Brentuximab vedotin can be decreased when combined with Methysergide.]
[P01AB01, metronidazole, The metabolism of Brentuximab vedotin can be decreased when combined with Metronidazole.]
[V04CD01, metyrapone, The metabolism of Brentuximab vedotin can be increased when combined with Metyrapone.]
[S02AA13, miconazole, The metabolism of Brentuximab vedotin can be decreased when combined with Miconazole.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Brentuximab vedotin.]
[G03XB01, mifepristone, The serum concentration of Brentuximab vedotin can be increased when it is combined with Mifepristone.]
[J01FA11, miocamycin, The metabolism of Brentuximab vedotin can be decreased when combined with Miocamycin.]
[L01XX23, mitotane, The metabolism of Brentuximab vedotin can be increased when combined with Mitotane.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Brentuximab vedotin.]
[L03AC01, aldesleukin, The metabolism of Brentuximab vedotin can be decreased when combined with Aldesleukin.]
[C01BD01, amiodarone, The serum concentration of Brentuximab vedotin can be increased when it is combined with Amiodarone.]
[N02AA01, morphine, The serum concentration of Brentuximab vedotin can be increased when it is combined with Morphine.]
[L04AB05, certolizumab pegol, The metabolism of Brentuximab vedotin can be increased when combined with Certolizumab pegol.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Ofatumumab is combined with Brentuximab vedotin.]
[L01EX03, pazopanib, The metabolism of Brentuximab vedotin can be decreased when combined with Pazopanib.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Brentuximab vedotin.]
[N05CA02, amobarbital, The metabolism of Brentuximab vedotin can be increased when combined with Amobarbital.]
[G04CA04, silodosin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Silodosin.]
[G03XC01, raloxifene, The metabolism of Brentuximab vedotin can be decreased when combined with Raloxifene.]
[N03AB05, fosphenytoin, The metabolism of Brentuximab vedotin can be increased when combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Brentuximab vedotin.]
[J01CF06, nafcillin, The metabolism of Brentuximab vedotin can be increased when combined with Nafcillin.]
[V03AB15, naloxone, The metabolism of Brentuximab vedotin can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Brentuximab vedotin can be increased when combined with Anakinra.]
[A10BG01, troglitazone, The metabolism of Brentuximab vedotin can be increased when combined with Troglitazone.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Brentuximab vedotin.]
[L01CD02, docetaxel, The metabolism of Brentuximab vedotin can be decreased when combined with Docetaxel.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Brentuximab vedotin.]
[N06AX23, desvenlafaxine, The metabolism of Brentuximab vedotin can be decreased when combined with Desvenlafaxine.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Brentuximab vedotin.]
[C10AD02, niacin, The metabolism of Brentuximab vedotin can be decreased when combined with Niacin.]
[C08CA04, nicardipine, The metabolism of Brentuximab vedotin can be decreased when combined with Nicardipine.]
[G03DC02, norethindrone, The metabolism of Brentuximab vedotin can be decreased when combined with Norethisterone.]
[C02KX01, bosentan, The metabolism of Brentuximab vedotin can be increased when combined with Bosentan.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Brentuximab vedotin.]
[R05DA07, noscapine, The metabolism of Brentuximab vedotin can be decreased when combined with Noscapine.]
[A16AX07, sapropterin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Sapropterin.]
[H01CB02, octreotide, The serum concentration of Brentuximab vedotin can be increased when it is combined with Octreotide.]
[J01FA05, oleandomycin, The metabolism of Brentuximab vedotin can be decreased when combined with Oleandomycin.]
[L04AC04, rilonacept, The metabolism of Brentuximab vedotin can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Brentuximab vedotin can be increased when combined with Omeprazole.]
[H02AB05, paramethasone, The metabolism of Brentuximab vedotin can be increased when combined with Paramethasone.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Penicillamine is combined with Brentuximab vedotin.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Brentuximab vedotin.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Brentuximab vedotin.]
[N05CA01, pentobarbital, The metabolism of Brentuximab vedotin can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Pentostatin is combined with Brentuximab vedotin.]
[L01FX01, edrecolomab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Edrecolomab.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Brentuximab vedotin.]
[N03AA02, phenobarbital, The metabolism of Brentuximab vedotin can be increased when combined with Phenobarbital.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Brentuximab vedotin.]
[M02AA01, phenylbutazone, The metabolism of Brentuximab vedotin can be increased when combined with Phenylbutazone.]
[N03AB02, phenytoin, The metabolism of Brentuximab vedotin can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Brentuximab vedotin can be increased when combined with Golimumab.]
[L02BB03, bicalutamide, The metabolism of Brentuximab vedotin can be decreased when combined with Bicalutamide.]
[C08CX01, mibefradil, The serum concentration of Brentuximab vedotin can be increased when it is combined with Mibefradil.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Brentuximab vedotin.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Brentuximab vedotin.]
[J05AE01, saquinavir, The serum concentration of Brentuximab vedotin can be increased when it is combined with Saquinavir.]
[J05AG02, delavirdine, The metabolism of Brentuximab vedotin can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Brentuximab vedotin can be decreased when combined with Irbesartan.]
[B01AC13, abciximab, The risk or severity of adverse effects can be increased when Abciximab is combined with Brentuximab vedotin.]
[L04AC05, ustekinumab, The risk or severity of adverse effects can be increased when Ustekinumab is combined with Brentuximab vedotin.]
[L04AC08, canakinumab, The metabolism of Brentuximab vedotin can be increased when combined with Canakinumab.]
[J05AE03, ritonavir, The serum concentration of Brentuximab vedotin can be increased when it is combined with Ritonavir.]
[S03BA02, prednisolone, The metabolism of Brentuximab vedotin can be increased when combined with Prednisolone.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Prednisone is combined with Brentuximab vedotin.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Brentuximab vedotin can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Brentuximab vedotin can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Brentuximab vedotin can be increased when combined with Probenecid.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Brentuximab vedotin.]
[C10AB05, fenofibrate, The metabolism of Brentuximab vedotin can be decreased when combined with Fenofibrate.]
[C01BC03, propafenone, The serum concentration of Brentuximab vedotin can be increased when it is combined with Propafenone.]
[R06AX26, fexofenadine, The serum concentration of Brentuximab vedotin can be increased when it is combined with Fexofenadine.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be decreased when combined with Brentuximab vedotin.]
[N01AX10, propofol, The metabolism of Brentuximab vedotin can be decreased when combined with Propofol.]
[N02AC04, propoxyphene, The metabolism of Brentuximab vedotin can be decreased when combined with Dextropropoxyphene.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Brentuximab vedotin.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Brentuximab vedotin.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Brentuximab vedotin.]
[C01BA01, quinidine, The serum concentration of Brentuximab vedotin can be increased when it is combined with Quinidine.]
[P01BC01, quinine, The serum concentration of Brentuximab vedotin can be increased when it is combined with Quinine.]
[C02AA02, reserpine, The serum concentration of Brentuximab vedotin can be increased when it is combined with Reserpine.]
[J04AB02, rifampin, The serum concentration of Brentuximab vedotin can be decreased when it is combined with Rifampicin.]
[J01FA06, roxithromycin, The metabolism of Brentuximab vedotin can be decreased when combined with Roxithromycin.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Brentuximab vedotin.]
[N05CA06, secobarbital, The metabolism of Brentuximab vedotin can be increased when combined with Secobarbital.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Obinutuzumab.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Brentuximab vedotin.]
[H01CB01, somatostatin, The metabolism of Brentuximab vedotin can be decreased when combined with Somatostatin.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Brentuximab vedotin.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Brentuximab vedotin.]
[N03AG01, valproic acid, The metabolism of Brentuximab vedotin can be decreased when combined with Valproic acid.]
[D07AB02, hydrocortisone butyrate, The metabolism of Brentuximab vedotin can be increased when combined with Hydrocortisone butyrate.]
